skip to content »

Lester and Sue Smith Breast Center

Houston, Texas

The Lester and Sue Smith Breast Center's mission is to improve prevention, diagnosis and treatment of breast disease.
Lester & Sue Smith Breast Center
not shown on screen

Breast Cancer Research

A major goal of the Lester and Sue Smith Breast Center is to eliminate breast cancer as a disease of public health proportions. In order to make further progress we need to have a better understanding of the environmental influences, as well as the genes which contribute to breast cancer development and aggressiveness. A better understanding of the molecular pathways controlling important cellular events, such as cell survival, cell proliferation, differentiation and apoptosis is also crucial. Finally, the role of supporting tissues in the tumor, such as stromal components, myoepithelium, and angiogenesis is important. To increase our knowledge of the biology of breast cancer, the center has established a research agenda that covers a broad array of important research areas.

Normal mammary gland development

An understanding of factors which regulate growth and development of normal breast cells could provide important clues to better understanding the causes of breast cancer.

Biology of premalignant breast disease

We know that breast cancer evolves through a series of stages of increasingly abnormal breast ductal cells. Understanding the biological and molecular alterations underlying premalignant disease could lead to new strategies to prevent cancers from forming and new diagnostic markers useful to physicians.

Genetics of premalignant disease

Identification of a panel of molecular alterations contributing to breast cancer development could lead to genetic markers that will predict which women are most likely to acquire breast cancer in their lifetimes. These women could then be targeted for breast cancer prevention.


Methods to block the effects of estrogen have been shown to be effective in preventing some breast cancers. Studies are underway to block alternative molecular pathways that are also important in growth regulation, differentiation and cell death, as additional means of prevention.

Oncogenes and suppressor genes

Identification of the genes that when over expressed (oncogenes) or lost (tumor suppressor genes) lead to breast cancer could provide important clues to the causes of breast cancer as well as new treatment and prevention strategies.

Growth regulation by polypeptide growth factors

The female hormone, estrogen, a steroid hormone, is crucial for breast cancer development and progression, but other factors are also important. Polypeptide growth factors that mediate their effects through membrane receptors contribute important proliferative and cell survival signals that could also be potential targets for diagnosis and treatment. Understanding how these factors function and how they cooperate with estrogen signaling pathways is an important research area.

Transcriptional regulation

The expression of genes and their encoded proteins that regulate important cellular effects is controlled by a complex process involving a panoply of transcription factors. A better understanding of these very basic cellular events in breast cancer could also provide important diagnostic and treatment targets.

Structure and function of estrogen receptor (ERα and ERβ)

Estrogen is a major contributor to the development of breast cancer. This hormone mediates its effects by binding to nuclear receptors, of which there are now at least two known types, ERα and ERβ. These important transcription factors regulate the growth of breast cancer, and their activities are modulated by a large number of other receptor-interacting proteins that can activate or repress function. A basic understanding of these pathways could lead to new methods of prevention or treatment and a better understanding of how tumors become resistant to treatments designed to block estrogen's effects.

Mechanisms of hormonal resistance

Drugs, such as tamoxifen, designed to block estrogen's effects or treatments designed to lower the estrogen levels in patients are effective treatment modalities, but many tumors eventually develop resistance. A better understanding of the molecular events in this resistance could lead to markers of resistance and to the development of new drugs to overcome or prevent resistance.

Selective estrogen receptor modulators (SERMs)

Tamoxifen was the first SERM used in breast cancer treatment and prevention, but resistance develops in many patients and tamoxifen has some side effects. The development of other, similar drugs, known as selective estrogen receptor modulators, that are either more potent and or less toxic, is an important research area. Faslodex, a SERM with more potent antiestrogenic qualities, was developed in preclinical studies in the Center. Phase III clinical trials in patients now are showing it to be among the most effective treatments available.

Angiogenesis in breast cancer

Breast cancer, like other cancers, relies on the development of new blood vessels to support tumor growth. Preliminary data suggests that by inhibiting this process some tumors can be effectively treated. A better understanding of angiogenesis at the molecular level could have a profound impact for the development of new treatment strategies. Preliminary data also suggests that factors regulating angiogenesis may contribute to tamoxifen resistance.


The ability of some breast cancers to metastasize to other sites in the body accounts for breast cancer mortality. However, not all patients have such metastases and studies of this process could lead to ways of preventing the metastatic phenotype or new techniques for predicting which patients are likely to have metastases at diagnosis. Accurate identification of these patients would be very important to clinicians, since only patients with metastases would need systemic chemotherapy or hormonal therapy after surgery.

Prognostic and predictive biomarkers

Breast cancers are very heterogeneous in their aggressiveness and treatment response. These differences among patients can be accounted for by the particular set of genetic alterations in an individual patient's tumor. Identification of each tumor's molecular fingerprint, then, could help to segregate patients who have particularly aggressive tumors or who need to be treated with specific therapies. A major goal of Breast Center research is to translate the information learned in the laboratory about the genetic alterations in breast cancer and, then, develop clinically useful assays, or molecular profile, to help clinicians make treatment decisions. Faculty in the Breast Center have already contributed much of the seminal information on assays that are currently used in patients, such as estrogen and progesterone receptors, the HER-2 oncogene and proliferation markers. Now, with the ability to investigate thousands of genes on an individual tumor using microarray technology, more complete molecular profiling of a patient's tumor is possible.

E-mail this page to a friend